The National Institute for Health and Care Excellence (NICE) has announced that it does not recommend larotrectinib (Vitrakvi) for the treatment of advanced NTRK
fusion–positive solid tumors in adults and children without satisfactory treatment options.1
- Appraisal consultation document: Larotrectinib for treating NTRK fusion-positive solid tumors. National Institute for Health and Care Excellence. Posted January 17, 2020. bit.ly/2FXJWdp. Accessed January 17, 2020.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. doi: 10.1056/NEJMoa1714448.
- Hyman DM, van Tilburg CM, Albert CM, et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol. 2019;30(suppl 5; abstr 445PD). doi: 10.1093/annonc/mdz244.007.
... to read the full story